2 mg nicotine gum + 4 mg nicotine gum

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Dental Pellicle

Conditions

Dental Pellicle

Trial Timeline

Jul 1, 2005 → Sep 1, 2005

About 2 mg nicotine gum + 4 mg nicotine gum

2 mg nicotine gum + 4 mg nicotine gum is a approved stage product being developed by Johnson & Johnson for Dental Pellicle. The current trial status is completed. This product is registered under clinical trial identifier NCT00174499. Target conditions include Dental Pellicle.

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00174499ApprovedCompleted

Competing Products

20 competing products in Dental Pellicle

See all competitors
ProductCompanyStageHype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
40
Sodium Fluoride DentifriceJohnson & JohnsonPre-clinical
26
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
40
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + PlaceboJohnson & JohnsonPhase 2
35
Acetaminophen ER + PlaceboJohnson & JohnsonPhase 2
35
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3
40
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3
40
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
35
Pregabalin + Alprazolam + PlaceboPfizerPhase 2
35
Prototype (AN0128 Toothpaste)PfizerPhase 1
29
PF-05089771 + PF-05089771 + PF-05089771 + IbuprofenPfizerPhase 2
35
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
35
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
27
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3
37
XPF-001 + placeboXenon PharmaceuticalsPhase 2
32
N1539 + placebo + N1539 + N1539 + MotrinAlkermesPhase 2
32
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3
34
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + PlaceboAFT PharmaceuticalsPhase 2
17
Maxigesic 325 + Acetaminophen + Ibuprofen + PlaceboAFT PharmaceuticalsPhase 3
30
C16G2 GelArmata PharmaceuticalsPhase 2
25